201 related articles for article (PubMed ID: 23167780)
1. Efficacy of low- and high-dose trilostane treatment in dogs (< 5 kg) with pituitary-dependent hyperadrenocorticism.
Cho KD; Kang JH; Chang D; Na KJ; Yang MP
J Vet Intern Med; 2013; 27(1):91-8. PubMed ID: 23167780
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of 2 trilostane protocols for the treatment of canine pituitary-dependent hyperadrenocorticism: twice daily versus once daily.
Arenas C; Melián C; Pérez-Alenza MD
J Vet Intern Med; 2013; 27(6):1478-85. PubMed ID: 24118316
[TBL] [Abstract][Full Text] [Related]
3. Results of clinical examinations, laboratory tests, and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane.
Ruckstuhl NS; Nett CS; Reusch CE
Am J Vet Res; 2002 Apr; 63(4):506-12. PubMed ID: 11939311
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of twice-daily, low-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism.
Vaughan MA; Feldman EC; Hoar BR; Nelson RW
J Am Vet Med Assoc; 2008 May; 232(9):1321-8. PubMed ID: 18447776
[TBL] [Abstract][Full Text] [Related]
5. Serum concentrations of cortisol and cortisone in healthy dogs and dogs with pituitary-dependent hyperadrenocorticism treated with trilostane.
Sieber-Ruckstuhl NS; Boretti FS; Wenger M; Maser-Gluth C; Reusch CE
Vet Rec; 2008 Oct; 163(16):477-81. PubMed ID: 18931355
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of twice-daily lower-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism.
Feldman EC
J Am Vet Med Assoc; 2011 Jun; 238(11):1441-51. PubMed ID: 21627507
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy of trilostane administered twice daily in dogs with pituitary-dependent hyperadrenocorticism.
Alenza DP; Arenas C; Lopez ML; Melian C
J Am Anim Hosp Assoc; 2006; 42(4):269-76. PubMed ID: 16822765
[TBL] [Abstract][Full Text] [Related]
8. Cortisol, aldosterone, cortisol precursor, androgen and endogenous ACTH concentrations in dogs with pituitary-dependant hyperadrenocorticism treated with trilostane.
Sieber-Ruckstuhl NS; Boretti FS; Wenger M; Maser-Gluth C; Reusch CE
Domest Anim Endocrinol; 2006 Jul; 31(1):63-75. PubMed ID: 16233969
[TBL] [Abstract][Full Text] [Related]
9. Effect of trilostane on hormone and serum electrolyte concentrations in dogs with pituitary-dependent hyperadrenocorticism.
Griebsch C; Lehnert C; Williams GJ; Failing K; Neiger R
J Vet Intern Med; 2014; 28(1):160-5. PubMed ID: 24341822
[TBL] [Abstract][Full Text] [Related]
10. Trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism.
Braddock JA; Church DB; Robertson ID; Watson AD
Aust Vet J; 2003 Oct; 81(10):600-7. PubMed ID: 15080470
[TBL] [Abstract][Full Text] [Related]
11. Update on the use of trilostane in dogs.
Lemetayer J; Blois S
Can Vet J; 2018 Apr; 59(4):397-407. PubMed ID: 29606727
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the use of baseline cortisol concentration as a monitoring tool for dogs receiving trilostane as a treatment for hyperadrenocorticism.
Cook AK; Bond KG
J Am Vet Med Assoc; 2010 Oct; 237(7):801-5. PubMed ID: 20919845
[TBL] [Abstract][Full Text] [Related]
13. Laboratory assessment of trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism.
Arenas Bermejo C; Pérez Alenza D; García San José P; Llauet L; Pérez-López L; Melián C; C Feldman E
J Vet Intern Med; 2020 Jul; 34(4):1413-1422. PubMed ID: 32533623
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of baseline cortisol concentration to monitor efficacy of twice-daily administration of trilostane to dogs with pituitary-dependent hyperadrenocorticism: 22 cases (2008-2012).
Woolcock AD; Bugbee AC; Creevy KE
J Am Vet Med Assoc; 2016 Apr; 248(7):814-21. PubMed ID: 27003023
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Survival Times for Dogs with Pituitary-Dependent Hyperadrenocorticism in a Primary-Care Hospital: Treated with Trilostane versus Untreated.
Nagata N; Kojima K; Yuki M
J Vet Intern Med; 2017 Jan; 31(1):22-28. PubMed ID: 27906457
[TBL] [Abstract][Full Text] [Related]
16. Lack of association between clinical signs and laboratory parameters in dogs with hyperadrenocorticism before and during trilostane treatment.
Boretti FS; Holzthüm J; Reusch CE; Sieber-Ruckstuhl NS
Schweiz Arch Tierheilkd; 2016 Sep; 158(9):631-638. PubMed ID: 27655162
[TBL] [Abstract][Full Text] [Related]
17. Effect of trilostane on serum concentrations of aldosterone, cortisol, and potassium in dogs with pituitary-dependent hyperadrenocorticism.
Wenger M; Sieber-Ruckstuhl NS; Müller C; Reusch CE
Am J Vet Res; 2004 Sep; 65(9):1245-50. PubMed ID: 15478772
[TBL] [Abstract][Full Text] [Related]
18. The effect of 1 year of trilostane treatment on peripheral lymphocyte subsets in dogs with pituitary-dependent hyperadrenocorticism.
Oda H; Mori A; Shono S; Onozawa E; Sako T
J Vet Med Sci; 2016 Jun; 78(5):851-4. PubMed ID: 26782012
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two treatment regimens with trilostane in dogs with pituitary-dependent hyperadrenocorticism.
Braun C; Boretti FS; Reusch CE; Sieber-Ruckstuhl NS
Schweiz Arch Tierheilkd; 2013 Oct; 155(10):551-8. PubMed ID: 24091230
[TBL] [Abstract][Full Text] [Related]
20. Serum cholecystokinin concentrations in dogs with naturally acquired pituitary-dependent hyperadrenocorticism.
Noh S; Kim HS; Chang J; Kang JH; Chang D; Yang MP
Am J Vet Res; 2016 Oct; 77(10):1101-7. PubMed ID: 27668581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
